{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:25:58Z","timestamp":1767774358193,"version":"build-2238731810"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Unprecedented immunization campaigns have been rolled out worldwide in an attempt to contain the ongoing COVID-19 pandemic. Multiple vaccines were brought to the market, among two utilizing novel messenger ribonucleic acid technology. Despite their undisputed success in decreasing COVID-19-associated hospitalizations and mortality, various adverse events have been reported. The emergence of malignant lymphoma is one of such rare adverse events that has raised concern, although an understanding of the mechanisms potentially involved remains lacking. Herein, we present the first case of B-cell lymphoblastic lymphoma following intravenous high-dose mRNA COVID-19 vaccination (BNT162b2) in a BALB\/c mouse. Two days following booster vaccination (\n                    <jats:italic>i.e.<\/jats:italic>\n                    , 16 days after prime), at only 14 weeks of age, our animal suffered spontaneous death with marked organomegaly and diffuse malignant infiltration of multiple extranodal organs (heart, lung, liver, kidney, spleen) by lymphoid neoplasm. Immunohistochemical examination revealed organ sections positive for CD19, terminal deoxynucleotidyl transferase, and c-MYC, compatible with a B-cell lymphoblastic lymphoma immunophenotype. Our murine case adds to previous clinical reports on malignant lymphoma development following novel mRNA COVID-19 vaccination, although a demonstration of direct causality remains difficult. Extra vigilance is required, with conscientious reporting of similar cases and a further investigation of the mechanisms of action explaining the aforementioned association.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2023.1158124","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:32:45Z","timestamp":1682901165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB\/c mouse: A case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Sander","family":"Eens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Van Hecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasper","family":"Favere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Tousseyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter-Jan","family":"Guns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Roskams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hein","family":"Heidbuchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1835469","article-title":"Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease","volume":"20","author":"Bhagat","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-138234","article-title":"Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)","volume":"96","author":"Umakanthan","year":"2020","journal-title":"Postgraduate Med J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2021-140654","article-title":"Review of COVID-19 vaccine subtypes, efficacy and geographical distributions","volume":"98","author":"Francis","year":"2022","journal-title":"Postgraduate Med J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.870599","article-title":"Profiling COVID-19 vaccine adverse events by statistical and ontological analysis of VAERS case reports","volume":"13","author":"Guo","year":"2022","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat Hum Behav"},{"key":"B8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/medicina59010157","article-title":"Non-Hodgkin lymphoma developed shortly after mRNA COVID-19 vaccination: report of a case and review of the literature","volume":"59","author":"Cavanna","year":"2023","journal-title":"Medicina"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab941","article-title":"Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in mouse model (vol 73, pg 2372, 2021)","volume":"73","author":"Li","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-224570","article-title":"Terminal deoxynucleotidyl transferase (TdT)-negative T-cell lymphoblastic lymphoma with loss of the T-cell lineage-specific marker CD3 at relapse: a rare entity with an aggressive outcome","volume":"2018","author":"Hassan","year":"2018","journal-title":"BMJ Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in b-cell lymphomas: diagnostic and molecular aspects","volume":"8","author":"Nguyen","year":"2017","journal-title":"Genes (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5774","article-title":"MYC-driven aggressive b-cell lymphomas: biology, entity, differential diagnosis and clinical management","volume":"6","author":"Cai","year":"2015","journal-title":"Oncotarget"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-021-01168-x","article-title":"Lymphoblastic lymphoma: a concise review","volume":"24","author":"Intermesoli","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.12.003","article-title":"Lymphoblastic lymphoma","volume":"79","author":"Cortelazzo","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2017.11929639","article-title":"B-lymphoblastic lymphoma of the rectum","volume":"30","author":"Unnikrishnan","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1309\/Q5GV-3K00-WAC6-BBUB","article-title":"Precursor b-cell lymphoblastic lymphoma. a study of nine cases lacking blood and bone marrow involvement and review of the literature","volume":"115","author":"Maitra","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18136","article-title":"Two cases of axillary lymphadenopathy diagnosed as diffuse large b-cell lymphoma developed shortly after BNT162b2 COVID-19 vaccination","volume":"36","author":"Mizutani","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58070874","article-title":"Hematologic malignancies diagnosed in the context of the mRNA COVID-19 vaccination campaign: a report of two cases","volume":"58","author":"Zamfir","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.963393","article-title":"Rapid progression of marginal zone b-cell lymphoma after COVID-19 vaccination (BNT162b2): a case report","volume":"9","author":"Sekizawa","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18246","article-title":"Complete remission of primary cutaneous follicle centre cell lymphoma associated with COVID-19 vaccine","volume":"36","author":"Aouali","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2021.09.006","article-title":"A case report of posttransplant lymphoproliferative disorder after AstraZeneca coronavirus disease 2019 vaccine in a heart transplant recipient","volume":"54","author":"Tang","year":"2022","journal-title":"Transplant Proc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.798095","article-title":"Rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot: a case report","volume":"8","author":"Goldman","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1924371","article-title":"Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination","volume":"62","author":"Brumfiel","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20630","article-title":"Primary cutaneous anaplastic large-cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination","volume":"185","author":"Gambichler","year":"2021","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17736","article-title":"Recurrence of cutaneous T-cell lymphoma post viral vector COVID-19 vaccination","volume":"36","author":"Panou","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jdcr.2022.08.006","article-title":"Subcutaneous panniculitis-like T-cell lymphoma after COVID-19 vaccination","volume":"28","author":"Kreher","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18615","article-title":"Anaplastic large cell lymphoma at the SARS-CoV2 vaccine injection site","volume":"37","author":"Revenga-Porcel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.036","article-title":"Cutaneous lymphoid hyperplasia and marginal zone b-cell lymphoma following vaccination","volume":"53","author":"May","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-008-9259-x","article-title":"Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study","volume":"20","author":"Lankes","year":"2009","journal-title":"Cancer Causes Control"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050435","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/encyclopedia2010028","article-title":"Adverse events profile of COVID-19 preventative strategies","volume":"2","author":"Ajmera","year":"2022","journal-title":"Encyclopedia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3109\/10408448609037464","article-title":"Immunomorphologic classification of spontaneous lymphoid cell neoplasms occurring in female BALB\/c mice","volume":"70","author":"Pattengale","year":"1983","journal-title":"J Natl Cancer Inst"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/21.3.404","article-title":"Longevity and gross pathology at death in 22 inbred mouse strains","volume":"21","author":"Storer","year":"1966","journal-title":"J Gerontol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1963.tb13421.x","article-title":"Spontaneous cancer in mice","volume":"108","author":"Hoag","year":"1963","journal-title":"Ann N Y Acad Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2021-141119","article-title":"Inadvertent injection of COVID-19 vaccine into deltoid muscle vasculature may result in vaccine distribution to distance tissues and consequent adverse reactions","volume":"98","author":"Merchant","year":"2022","journal-title":"Postgrad Med J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/cid\/ciac133","article-title":"Reply to yau et\u00a0al","volume":"75","author":"Li","year":"2022","journal-title":"Clin Infect Dis"}],"updated-by":[{"DOI":"10.3389\/fonc.2023.1267904","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1158124\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:32:47Z","timestamp":1682901167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1158124\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":39,"alternative-id":["10.3389\/fonc.2023.1158124"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1158124","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"article-number":"1158124"}}